Literature DB >> 3711548

Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine.

R W Cohen, D L Rosenstreich.   

Abstract

To study the ability of cutaneous mast cells to degranulate in urticaria-prone patients, subjects were skin tested with the known mast cell degranulator, codeine sulfate. Sensitivity to codeine as determined by the concentrations of codeine necessary to cause a net wheal of 5 mm was compared between urticaria-prone subjects, allergic subjects, and normal control subjects. Urticaria-prone subjects were more sensitive to codeine at every concentration tested and exhibited a mean reactivity to codeine that was almost 100 times that of the other allergic individuals and normal control subjects. This difference could not be explained by an increased sensitivity to histamine in 71% of urticaria-prone patients nor by any dermatographic tendencies or increased relative allergic reactivity. These findings suggest that codeine skin testing can be used to identify a distinct population of patients with urticaria.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711548     DOI: 10.1016/0091-6749(86)90377-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Mast cells, neuropeptides and inflammation.

Authors:  M K Church; M A Lowman; P H Rees; R C Benyon
Journal:  Agents Actions       Date:  1989-04

2.  Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers.

Authors:  R E Polk; D Israel; J Wang; J Venitz; J Miller; J Stotka
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 3.  Basophil responsiveness in chronic urticaria.

Authors:  Sarbjit S Saini
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

4.  Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: Relationship to expression of Syk and SHIP-2.

Authors:  Sarbjit S Saini; Miya Paterniti; Kavitha Vasagar; Scott P Gibbons; Patricia M Sterba; Becky M Vonakis
Journal:  Clin Immunol       Date:  2009-05-27       Impact factor: 3.969

Review 5.  Basophils and skin disorders.

Authors:  Francesco Borriello; Francescopaolo Granata; Gianni Marone
Journal:  J Invest Dermatol       Date:  2014-02-06       Impact factor: 8.551

Review 6.  New concepts in chronic urticaria.

Authors:  Becky M Vonakis; Sarbjit S Saini
Journal:  Curr Opin Immunol       Date:  2008-10-17       Impact factor: 7.486

7.  Vibratory Urticaria Associated with a Missense Variant in ADGRE2.

Authors:  Steven E Boyden; Avanti Desai; Glenn Cruse; Michael L Young; Hyejeong C Bolan; Linda M Scott; A Robin Eisch; R Daniel Long; Chyi-Chia R Lee; Colleen L Satorius; Andrew J Pakstis; Ana Olivera; James C Mullikin; Eliane Chouery; André Mégarbané; Myrna Medlej-Hashim; Kenneth K Kidd; Daniel L Kastner; Dean D Metcalfe; Hirsh D Komarow
Journal:  N Engl J Med       Date:  2016-02-03       Impact factor: 91.245

8.  Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.

Authors:  Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2013-11-01       Impact factor: 10.793

9.  Association Between Helicobacter pylori-Negative Peptic Ulcer Disease and Chronic Urticaria: A Retrospective Observational Study.

Authors:  Chengguo Zhang; Yinbin Wei
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-10

Review 10.  Immunological events in chronic spontaneous urticaria.

Authors:  Marta Ferrer
Journal:  Clin Transl Allergy       Date:  2015-08-25       Impact factor: 5.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.